Heart Health Genetics

Your cholesterol numbers describe your body today. Your DNA describes the hand you were dealt at birth. This panel reads that hand, looking at inherited variations that nudge your cholesterol, blood fats, and artery risk up or down across your whole life.

Because genes do not change, this is close to a one-time test. Read early, it can flag a raised lifetime risk long before a standard lipid panel, or a calculator built on your current numbers, would catch it.

What This Panel Reveals

The panel answers one question from several angles: what did you inherit that shapes your heart risk? It combines two kinds of genetic information. The first is single-gene variants with large, well-understood effects. The second is polygenic risk scores, which add up hundreds of small variants into one number that estimates an inherited tendency.

The strongest single-gene markers sit in the cholesterol-clearing machinery. Variants in the LDL receptor gene (LDLR), and in APOB and PCSK9, are the classic causes of familial hypercholesterolemia (FH), an inherited pattern of very high LDL from birth. People who carry a rare protein-shortening change in APOB or PCSK9 have lower LDL cholesterol, roughly 34 to 74 mg/dL lower depending on the gene, and roughly 49% lower risk of coronary heart disease, which shows how powerfully these genes move risk in both directions. Two other high-value single-gene markers are APOE, which reshapes how you handle cholesterol and fat remnants, and the LPA gene, which largely sets your level of lipoprotein(a), a sticky, inherited cholesterol particle that drives artery disease on its own.

The polygenic scores widen the lens. There are separate scores for high cholesterol, high triglycerides (the main fat in blood), low HDL (the cholesterol that clears fat from arteries), high lipoprotein(a), combined high lipids, and weak reverse cholesterol transport (the body's cholesterol-removal system). These matter because most inherited lipid risk is not one dramatic mutation. It is spread thinly across many genes, and only a score can see the total.

The rest of the panel covers supporting biology: genes that regulate triglyceride clearance, fatty acid processing, liver fat, appetite and body weight, and a small group of drug-response genes that predict how you may react to common heart medications. These add context rather than a diagnosis, and most contribute only a small piece of the overall picture.

How to Read Your Results Together

No single marker tells the story. The value is in the combinations, because a rare high-impact variant and a high polygenic score add up. Someone with an FH-type variant can range from near-average risk to several times average, depending on the rest of their genetic background: across carriers, the chance of coronary artery disease (the plaque buildup behind most heart attacks) by age 75 spans from about 17% to about 78%.

One consistent theme runs through the lipid genes: risk tracks most closely with lifelong exposure to apolipoprotein B (apoB), the protein wrapped around each LDL and related particle. In genetic studies, lowering triglycerides through one pathway and lowering LDL through another cut heart risk by nearly the same amount for the same drop in apoB. That is why an isolated high-triglyceride score means less if the apoB-carrying particle count stays low.

What to Do with Your Results

Genetics sets the baseline; blood work measures where you actually stand. Pair this panel with a lipid panel, apoB, and a one-time lipoprotein(a) measurement to translate inherited tendency into current, treatable numbers. If a score or variant points to high risk, that is a reason to measure and act sooner, not to panic.

A high inherited risk is most useful when you are younger, because it can reclassify borderline cases. In adults under 50, those in the high coronary-score category carry roughly three to four times the heart attack risk of those in the low category, and the top few percent of a coronary score can reach risk comparable to people who already have heart disease. In one small, single-site trial, disclosing an integrated risk score that included a polygenic component was linked to more statin starts and fewer cardiovascular events over about a decade, a promising but not yet confirmed finding.

Bring an FH-type variant, a high coronary score, or a high lipoprotein(a) result to a physician or genetic counselor. These findings can justify earlier lipid-lowering therapy, a coronary calcium scan, and cascade testing of parents, siblings, and children, who each have a 50% chance of sharing a single-gene variant. The DNA itself needs testing only once; the lipids that reflect your changing, treatable risk should be rechecked at least yearly, and more often after any change in treatment or lifestyle.

When Results Can Be Misleading

Polygenic scores were mostly built in people of European ancestry and are less accurate in other groups. Read your scores as risk enhancers alongside blood tests and family history, not as a verdict.

Two cautions apply to specific markers. The MTHFR gene is widely included on genetic panels but has little proven value for predicting or managing heart disease, so an MTHFR result should not drive decisions on its own. And genes are not destiny: a high inherited risk responds to the same proven tools, from lipid-lowering therapy to lifestyle, and a low score does not cancel out smoking, high blood pressure, or a poor diet.